Kane Lawrence P
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
J Exp Med. 2025 Aug 4;222(8). doi: 10.1084/jem.20250896. Epub 2025 Jun 20.
In this issue of JEM, Zhang et al. (https://doi.org/10.1084/jem.20250339) report that a gain-of-function mutation in CARMIL2, previously identified in patients, is sufficient to replace the contribution of CD28 to NF-κB activation and downstream effects in T cells, including in the setting of an anti-tumor response.